University of the Ryukyus · Faculty of Medicine · 講師

Research keywords耳鼻咽喉・頭頸部外科・頭頸部癌

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Preliminary observations on peripheral inflammatory markers in NIR-PIT and ICI-treated recurrent head and neck squamous cell carcinoma2026 · Hitoshi Hirakawa, Taro Ikegami, Hidetoshi Kinjyo, Shinya Agena, Shunsuke Kondo, Norimoto Kise, Yuki Kayo, Hironori Nakayoshi, Takahiro Miyahira, Hiroyuki Maeda, Mikio Suzuki
• Modified EXTREME regimen versus modified TPEx regimen as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, open-label, randomized, exploratory study (TEMPER study)2026 · BACKGROUND: The EXTREME regimen is the standard first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC), but it is poorly tolerated in Asian patients. We aimed to compare the efficacy and safety of the modified EXTREME (mEXTREME) and modified TPEx (mTPEx) regimens in Japanese patients. METHODS: This was a multicenter, randomized, exploratory study. The dose of chemotherapeutic agents was reduced by 25% for the mEXTREME regimen compared to the EXTREME regimen and by 20% for the mTPEX regimen compared to the TPEx regimen. Six and four cycles were repeated every 21 days for the mEXTREME and mTPEx regimens, respectively. In both regimens, weekly 250 mg/m2 cetuximab was continued as maintenance therapy in case of disease control. RESULTS: Sixty-one patients were enrolled and assigned to the two treatment arms (30 to mEXTREME, 31 to mTPEx). Median PFS was 6.0 months and 5.3 months (p = 0.28), and median overall survival was 17.4 months and 18.7 months (p = 0.72) for the mEXTREME and mTPEx groups, respectively. Twenty-seven patients in the mEXTREME group and 29 patients in the mTPEx group had grade 3 or worse adverse events during chemotherapy (p = 0.61). Early tumor shrinkage was 20% in the mEXTREME group and 44% in the mTPEx group (p = 0.01). CONCLUSIONS: No significant differences in survival were observed between the two groups, with similar toxicity profiles. As early tumor shrinkage was favorable in the mTPEx group, the mTPEx regimen may be the first-line standard of care for Asian patients with R/M HNSCC, particularly those who are not candidates for up-front pembrolizumab due to CPS < 1 or the presence of immunologically related complications and those who need rapid tumor shrinkage to relieve tumor-related symptoms. TRIAL REGISTRATION: UMIN000025436.
• 特集 Up to date HPV関連中咽頭癌 【総論】 HPV関連中咽頭癌の発がんメカニズム2025 · 平川 仁, 池上 太郎, 鈴木 幹男
• 再発中咽頭癌および舌癌の頸部再発に対して免疫チェックポイント阻害薬治療後に光免疫療法が奏効した2例2021 · 光免疫療法（PIT）は，標準治療後の切除不能な局所進行頭頸部癌，または治療困難な局所再発頭頸部癌に対して2021年1月に日本で承認された治療である。PITは免疫機構を誘導し，免疫チェックポイント阻害薬（ICI）と併用することで効果が増強される可能性がある。今回われわれは，ICI後にPITを行い著効した2例を経験した。症例1は中咽頭癌，局所再発部位に，症例2では中咽頭癌化学放射線治療歴のある舌癌術後の前頸部のリンパ節転移に治療を行った。現在，観察期間は短いものの完全奏効を維持している。それぞれの治療のタイミングに一定の見解はないが，ICI後のPITは有効な選択肢と考える。

• 頭頸部癌の癌幹細胞を標的にした新規薬物治療の開発2024 · 基盤研究(C)
• Torinを中心としたmTOR阻害薬による頭頸部癌新規低侵襲治療の開発2024 · 基盤研究(C)
• IP関連副鼻腔癌のExon20insによる癌化メカニズムの解明と新規治療戦略
• 内反性乳頭腫関連副鼻腔癌におけるExon20ins発癌機構の解明および新規の治療戦略

• Official profile